GRAPL

Model summary

A soluble adaptor that shuttles between the cytosol and plasma membrane to assemble inhibitory and trafficking complexes. Its N-terminal module binds proline-rich motifs while a central phosphotyrosine-recognition module anchors to phosphorylated signaling hubs, creating multivalent assemblies that dampen ERK pathway output and channel signaling proteins toward ubiquitin–proteasome degradation. By coordinating endocytic and proteostatic routes, it terminates receptor-driven signals and maintains pathway fidelity.

Predicted Gene Ontology terms

1. 01

   I begin with the InterPro architecture.

   The N-terminus carries IPR001452 (SH3 domain, residues 1–58) embedded within IPR036028 (SH3-like domain superfamily, residues 4–78) and further specified by IPR035645 (GRAP, N-terminal SH3 domain, residues 2–55). Immediately downstream lies IPR000980 (SH2 domain, residues 58–118) encompassed by IPR036860 (SH2 domain superfamily, residues 61–108). The overall fold and lineage are captured by IPR043539 (Grb2-like family, residues 1–103), indicating a compact SH3–SH2 tandem typical of Src-homology adaptor proteins. The ordered SH3→SH2 arrangement causes avid, multivalent protein binding: the SH3 domain recognizes proline-rich motifs, while the SH2 domain binds phosphotyrosine-containing sequences. This tandem architecture enforces GO:0005515 protein binding as the molecular function by creating a high-affinity scaffold that nucleates signaling and trafficking assemblies.

2. 02

   From this binding logic, I infer two coupled biological roles.

   First, the SH3–SH2 scaffold can attenuate MAPK signaling by assembling inhibitory complexes that divert or terminate ERK pathway flow. This mechanistic capacity aligns with GO:0070373 negative regulation of ERK1 and ERK2 cascade: SH2-mediated capture of phosphorylated signaling nodes and SH3-mediated recruitment of inhibitory or endocytic machinery together dampen ERK output. Second, the same scaffold can promote proteasome-directed turnover of signaling proteins. By docking ubiquitin–proteasome pathway components onto phosphorylated substrates and their adaptors, it enhances selective degradation, consistent with GO:0032436 positive regulation of proteasomal ubiquitin-dependent protein catabolic process. Thus, the domain architecture directly drives both pathway attenuation and proteostasis.

3. 03

   Cellular placement follows from the modular design and known trafficking behavior of SH3–SH2 adaptors.

   The absence of transmembrane segments and the soluble nature of SH3/SH2 modules support a cytosolic pool, matching GO:0005829 cytosol. Transient membrane association arises when SH2 domains engage phosphorylated receptors and endocytic adaptors, situating the protein at the GO:0005886 plasma membrane during receptor internalization and signaling termination. This cytosol-to-membrane shuttling is a hallmark of signal-adaptor dynamics.

4. 04

   Mechanistically, I hypothesize that the SH3 domain captures proline-rich endocytic and cytoskeletal adaptors, while the SH2 domain anchors to tyrosine-phosphorylated receptors or scaffolds.

   This dual anchoring builds assemblies that both curtail ERK signaling and funnel pathway components toward ubiquitin-mediated proteasomal turnover. Likely partners include phosphorylated receptor tyrosine kinases and their adaptors at the membrane, followed by cytosolic ubiquitin–proteasome machinery and endocytic factors that collectively enforce downregulation of MAPK signaling.